EQS-Adhoc: Polyphor announces presentation of new survival data on balixafortide at the ASCO Annual Meeting 2019
EQS Group-Ad-hoc: Polyphor AG / Key word(s): Study results
Polyphor announces presentation of new survival data on balixafortide at the
ASCO Annual Meeting 2019
17-May-2019 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
_Allschwil, Switzerland, May 17, 2019_
*Polyphor announces presentation of new survival data on balixafortide at
the ASCO Annual Meeting 2019*
Polyphor AG (SIX: POLN) today announced that it will present new clinical
data on survival outcomes of the Phase I trial of balixafortide, our lead
immuno-oncology candidate, in combination with eribulin in HER2 negative
metastatic breast cancer (MBC) at the 2019 American Society of Clinical
Oncology (ASCO) Annual Meeting being held in Chicago, May 31 - June 4, 2019.
The Phase Ib trial investigated balixafortide in combination with eribulin
in 56 patients with advanced HER2 negative MBC. The overall survival for the
expanded cohort was 50% at 18 months and 33.3% at 24 months, whereas the
overall survival for the overall efficacy population was 42.4% at 18 months
and 25% at 24 months. These data are consistent with the positive trend of
all efficacy read-outs observed in this study and safety information is
consistent with what was previously reported. Although inter-trial
comparisons should be interpreted with caution, these survival rates,
especially for the expanded cohort, are higher than those reported for
eribulin monotherapy in similar MBC populations.These promising results
suggest that balixafortide in combination with eribulin could potentially
provide a new treatment option in heavily pre-treated patients with HER2
The abstract will be presented during the session "Development Immunotherapy
and Tumor Immunobiology", on June 1, 8:00 AM - 11:00 AM:
*Abstract number and title:* #2606, poster Board: #250, "Balixafortide (a
CXCR4 antagonist) + eribulin in HER2 negative metastatic breast cancer
(MBC): survival outcomes of the Phase I trial".
"We are pleased with the selection of our abstract for presentation at this
year's ASCO meeting. At the AACR Congress in April we already presented data
derived from the analysis of patient samples and subsequent further studies
confirming that balixafortide is a potent modulator of the immune system.
Most breast cancer patients who received balixafortide showed a beneficial
increase in the number of lymphocytes and neutrophils, cell types that have
been both reported to support tumor cell elimination," commented Frank
Weber, Polyphor Director and a.i. Chief Medical and Development Officer.
"The data presented further confirms the unique profile of balixafortide and
its potential value in treatment of metastatic breast cancer - an area in
which there is still a substantial unmet medical need."
*For further information please contact:*
Chief Financial Officer
Tel: +41 61 567 16 67
Dynamics Group AG
Tel: +41 43 268 32 31
*About Balixafortide (POL6326)*
Balixafortide is a potent and highly selective antagonist of CXCR4, a
G-protein coupled receptor (GPCR) that regulates the trafficking and homing
of both cancer cells and cells of the patient's immune system. CXCR4 plays a
critical role in tumor growth, survival, angiogenesis and metastasis[i].
High CXCR4 levels have been detected in almost all human tumor types,
including breast cancer. High CXCR4 expression is known to correlate with
aggressive metastatic behavior of cancer cells and a poor prognosis[ii].
Balixafortide is being developed to improve therapy outcomes in cancer, when
used in combination with other agents. Balixafortide is the only CXCR4
antagonist in development for breast cancer and is the most advanced CXCR4
antagonist, being developed in solid tumors, being the first product
candidate to reach proof of concept. The molecule was discovered based on
Polyphor's proprietary macrocycle technology platform. Balixafortide showed
strong results in a Phase Ib/proof of concept clinical trial in combination
with eribulin in patients affected with advanced metastatic breast cancer.
The development path identified with the input of the FDA is to conduct a
single pivotal study to achieve approval in HER-2 negative metastatic breast
cancer patients who previously received at least two chemotherapeutic
regimens in the metastatic setting. Additionally, there is the possibility
of achieving an accelerated approval based on interim results. Polyphor is
also conducting preclinical work to establish the potential for
balixafortide in combination with other drugs and in other oncology
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the
discovery and development of antibiotics and immuno-oncology compounds. It
has discovered and is developing the OMPTA (Outer Membrane Protein Targeting
Antibiotics). The OMPTA are potentially the first new class of antibiotics
against Gram-negative bacteria to have reached phase III stage in the last
50 years. The company's lead OMPTA, murepavadin, (POL7080) is in Phase III
development against _Pseudomonas aeruginosa_ - recognized as a critical
priority 1 pathogen by WHO; in addition, Polyphor is developing a pipeline
of further preclinical antibiotics based on its OMPTA platform. In addition,
Polyphor is developing an immuno-oncology candidate, balixafortide
(POL6326), which is starting a Phase III trial in combination with eribulin
in patients with advanced breast cancer, and exploring in parallel its
potential for further combinations and indications. Polyphor is based in
Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN).
For more information, please visit www.polyphor.com .
This press release contains forward-looking statements which are based on
current assumptions and forecasts of the Polyphor management. Known and
unknown risks, uncertainties, and other factors could lead to material
differences between the forward-looking statements made here and the actual
development, in particular Polyphor's results, financial situation, and
performance. Readers are cautioned not to put undue reliance on
forward-looking statements, which speak only of the date of this
communication. Polyphor disclaims any intention or obligation to update and
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
[i] Otsuka S, Bebb G. J Thorac Oncol. 2008;3(12):1379-1383
[ii] Chatterjee S, Behnam Azad B, Nimmagadda S. Adv Cancer Res. 2014;
1 24:31 -82
Document: http://n.eqs.com/c/fncls.ssp?u=GXSDVRCRCO 
Document title: Polyphor_ASCO_Balixafortide_17.5.2019
End of ad hoc announcement
Company: Polyphor AG
Phone: +41 61 567 1600
Fax: +41 61 567 1601
Listed: SIX Swiss Exchange
EQS News ID: 812723
End of Announcement EQS Group News Service
812723 17-May-2019 CET/CEST
(END) Dow Jones Newswires
May 17, 2019 01:00 ET ( 05:00 GMT)
Das könnte Sie auch interessieren
Im Artikel erwähnt...
|Porträt - Chart - Firmenprofil|
Meistgelesenweitere oft gelesene Nachrichten
Wir machen Sie fit für die Börse!
Aktuelle Nachrichten, umfangreiche
Hintergrundinformationen und essentielles
Finanzwissen rund um das Thema Börse.
Teilen Sie diese Seite auf Facebook oder Twitter